Advertisement
Screener

Actuate Therapeutics, Inc. (ACTU) Increase (Decrease) in Other Current Assets

2.8 / 5 stars · 68/120 Roast Me

Actuate Therapeutics, Inc. Increase (Decrease) in Other Current Assets

Actuate Therapeutics, Inc. (ACTU) reported Increase (Decrease) in Other Current Assets of -$161.90 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2026-08-14

  • Actuate Therapeutics, Inc. increase (decrease) in other current assets for the quarter ending 2026-06-30 was -$63.34K.
  • Actuate Therapeutics, Inc. increase (decrease) in other current assets for the quarter ending 2026-03-31 was -$98.55K.
  • Actuate Therapeutics, Inc. increase (decrease) in other current assets for the quarter ending 2025-12-31 was -$35.24K.
  • Actuate Therapeutics, Inc. increase (decrease) in other current assets for the quarter ending 2025-09-30 was $323.33K, a 40.27% decline year-over-year.
  • Actuate Therapeutics, Inc. increase (decrease) in other current assets for fiscal 2025 was -$82.28K, a 115.54% decline from fiscal 2024.
  • Actuate Therapeutics, Inc. increase (decrease) in other current assets for fiscal 2024 was $529.37K, a 16646.95% increase from fiscal 2023.
  • Actuate Therapeutics, Inc. increase (decrease) in other current assets for fiscal 2023 was $3.16K.
Period endIncrease (Decrease) in Other Current Assets 3 monthIncrease (Decrease) in Other Current Assets 6 monthIncrease (Decrease) in Other Current Assets 9 monthIncrease (Decrease) in Other Current Assets 12 month
2026-06-30-$63.34K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$161.90K
10-Q · filed 2026-08-14
-$197.14K
derived: sum of 3 quarters · filed 2026-08-14
$126.20K
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$98.55K
10-Q · filed 2026-05-14
-$133.79K
derived: sum of 2 quarters · filed 2026-05-14
$189.54K
derived: sum of 3 quarters · filed 2026-05-14
$26.29K
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$35.24K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
$288.09K
derived: sum of 2 quarters · filed 2026-03-26
$124.84K
derived: sum of 3 quarters · filed 2026-08-14
-$82.28K
10-K · filed 2026-03-26
2025-09-30$323.33K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$160.08K
derived: sum of 2 quarters · filed 2026-08-14
-$47.04K
10-Q · filed 2025-11-13
-$220.09K
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$163.26K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$370.38K
10-Q · filed 2026-08-14
-$543.43K
derived: sum of 3 quarters · filed 2026-08-14
-$2.08K
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$207.12K
10-Q · filed 2026-05-14
-$380.17K
derived: sum of 2 quarters · filed 2026-05-14
$161.18K
derived: sum of 3 quarters · filed 2026-05-14
$239.38K
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$173.05K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
$368.30K
derived: sum of 2 quarters · filed 2026-03-26
$446.50K
derived: sum of 3 quarters · filed 2026-03-26
$529.37K
10-K · filed 2026-03-26
2024-09-30$541.35K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$619.56K
derived: sum of 2 quarters · filed 2025-11-13
$702.42K
10-Q · filed 2025-11-13
$709.39K
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$78.20K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$161.07K
10-Q · filed 2025-08-14
$168.04K
derived: sum of 3 quarters · filed 2025-08-14
$169.48K
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$82.87K
10-Q · filed 2025-05-15
$89.83K
derived: sum of 2 quarters · filed 2025-05-15
$91.27K
derived: sum of 3 quarters · filed 2025-05-15
2023-12-31$6.97K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13
$8.41K
derived: sum of 2 quarters · filed 2025-03-13
$3.16K
10-K · filed 2025-03-13
2023-09-30$1.44K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
-$3.81K
10-Q · filed 2024-11-13
2023-06-30-$5.25K
10-Q · filed 2024-09-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
Korsana Biosciences, Inc. (CYCN)United States$0.016B
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
MUSTANG BIO, INC. (MBIO)United States$0.013B